CD274 and head and neck squamous cell carcinoma: In 2016 and 2019, nivolumab and pembrolizumab, two antibodies targeting the PD‐1/PD‐L1 immune checkpoint axis, received FDA approval for first‐line single‐agent treatment for platinum‐refractory disease or r/m HNSCC, respectively [7, 8].